Alira Health

Alira Health

Immunoglobulin Fc-Fusion Proteins

Over the past decades, several monoclonal antibodies (MAbs) and MAb-derivative products have been approved for therapeutic use in the United States. Specifically, one class of antibody derivatives has acquired growing importance: Fc-fusion proteins.

The interest in Fc-fusion proteins lies in the fact that the potential therapeutic value of many proteins — including enzymes, receptors, cytokines, blood factors, and peptides — can be realized by fusing them to the Fc region of human immunoglobulin G.

Our experts published a series of articles in BioProcess International reviewing the state of the art of Fc – fusion proteins, including their structure and molecular design, manufacturing process and therapeutic uses:

Our experts behind the articles:
  • Angela Linderholm
  • Steven M. Chamow

Contact us to discover how our team’s comprehensive knowledge in biologics, MAbs, and Mab-derivative products can make a significant difference in your development journey.

Immunoglobulin FC Fusion Proteins

Scientific Articles
Category:
Published on:
November 20, 2023

Related news

Scientific Articles November 20, 2023
Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges
Our experts conducted a deep evaluation of IgG-like bsAbs including general advantages and disadvantages compared with MAbs and more.
CMC
Scientific Articles November 20, 2023
Immunoglobulin Fc-Fusion Proteins
Our experts published a series of articles in BioProcess International reviewing the state of the art of Fc – fusion proteins, including their structure and molecular design, manufacturing(...)
CMC
Scientific Articles November 14, 2023
Capture of CH1-Containing Bispecific Antibodies: Evaluating an Alternative to Protein A
In the article our team investigated the use of an alternative purification method for BsAbs – a commercially available CaptureSelect CH1-XL affinity resin.
CMC Drug Development
Webinars October 18, 2023
The Process of CDMO Selection for Antibody Development: Matching Capabilities to Need
In this webinar, you'll learn how to identify key solution features, define patient experience expectations, generate evidence, and more!
CDMO CMC
Events September 27, 2023
Advances in Biologics and CGT
We are excited to share that we will be joining the Networking Reception: Advances in Biologics and CGT hosted by Catalent.
Biologics CMC
Scientific Articles September 21, 2023
Essential Elements of Technology Transfer
Peter Alexander, Senior Consultant, CMC, co-authored an article about technology transfer categories, essential elements, and documentation.
CDMO CMC
Scientific Articles September 20, 2023
Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates
Our expert CMC team addresses the manufacturing challenges of ADCs in “Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates.”
CMC Drug Development
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.